Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy
Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy
复制标题
DOI：
10.1136/bjo.2007.122283
复制
发表时间：
2008-01-01
影响因子：
4.1
通讯作者：
Tano, Y.
中科院分区：
文献类型：
--
作者：
Gomi, F.;Sawa, M.;Tano, Y.
目的：本研究的目的是评估玻璃体内注射贝伐单抗治疗息肉状脉络膜血管病变（PCV）的短期疗效。方法：玻璃体内注射贝伐单抗（1 mg），11例PCV患者的11只眼睛在此回顾性，干预性病例系列。主要结果测量是注射后3个月吲哚菁绿色血管造影（IA）上息肉状血管的变化。治疗前、后行光学相干断层扫描（optical coherence tomography，OCT）测量中心凹高度，并对治疗前后的最佳矫正视力（best corrected visual acuity，BCVA）进行评价。注射后1个月，中心凹高度显著降低（p = 0.023），但在3个月时，未观察到显著降低，尽管在11只眼睛中的5只眼睛中进行了额外注射。3个月时的IA显示一只眼睛的息肉消退，但其他10只眼睛的残留或扩大的病变。结论：玻璃体内注射贝伐单抗可减少PCV积液，但对减少PCV脉络膜血管改变无效。
Aims: The aim of the study was to assess the short-term efficacy of intravitreal injections of bevacizumab for polypoidal choroidal vasculopathy (PCV).Methods: Intravitreal bevacizumab (1 mg) was injected into 11 eyes of 11 patients with PCV in this retrospective, interventional case series. The main outcome measure was the change in the polypoidal vessels on indocyanine green angiography (IA) 3 months after injection. The foveal height determined by optical coherence tomography and the best-corrected visual acuity (BCVA) also were evaluated before and after treatment.Results: At baseline, subretinal fluid was observed in five eyes and a pigment epithelial detachment in eight eyes. The foveal height 1 month after injection decreased significantly (p = 0.023), but at 3 months, no significant decrease was observed, although an additional injection was administrated in five of 11 eyes. The IA at 3 months showed resolution of polyps in one eye but residual or enlarged lesions in the other ten eyes. The BCVA did not improve significantly, although the subjects had relatively good BCVA at baseline (mean 0.45).Conclusion: Intravitreal injection of bevacizumab may reduce the fluid from PCV but seems to be ineffective for diminishing its choroidal vascular changes.